Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02902081 · ClinicalTrials.gov registry record · NA
Cannabidiol and Emotional Stimuli
A NA study of Drug Addiction, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT02902081 is a NA study of Drug Addiction that has completed, run by University of Chicago. The registered enrollment target is 38 participants, below the 105-participant average among 13 other Drug Addiction trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02902081, a NA study of Drug Addiction, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid compound found in marijuana, on responses to emotional stimuli. Both preclinical and clinical studies indicate that CBD may act to reduce anxiety without excessive sedative side-effects. Thus the investigators hypothesize that CBD may reduce responses specifically to negative emotional and social stimuli, including pictures and emotional faces, without altering responses to positive stimuli. To examine this, the investigators will administer placebo, 300mg, 600mg, and 900mg CBD to healthy normal adults in a double-blind within-subjects study. The investigators will measure subjective and subtle physical responses to positive and negative stimuli using measures that have been characterized with classic anxiety-reducing drugs and drugs of abuse. Further, the investigators will examine whether CBD-induced changes in these measures of emotional response relate to changes in actual behavior in a controlled social interaction. These results will allow the investigators to examine the potential usefulness of CBD as an anxiety-reducing drug, and suggest mechanisms by which CBD may reduce anxiety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02902081
The ClinicalTrials.gov registry entry for NCT02902081 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 13 other Drug Addiction trials with a reported enrollment target (64% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Addiction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02902081 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02902081 about?
NCT02902081 is a clinical study titled "Cannabidiol and Emotional Stimuli". The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid compound found in marijuana, on responses to emotional stimuli. Both preclinical and clinical studies indicate that CBD may act to reduce anxiety without excessive sedative side-effects. Thus the investigators ...
What is the current status of trial NCT02902081?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2013-02. Estimated completion is 2017-03.
What conditions does trial NCT02902081 study?
This clinical trial studies the following conditions: Drug Addiction.
What interventions are being tested in trial NCT02902081?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT02902081?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02902081 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Treatment of Opioid Use Disorder
RECRUITING · NA
-
AWAITS: A Web-based E-health Application for Active Illicit Opioid Users
COMPLETED · NA
-
Innovative Digital Therapeutic for Smoking Cessation
COMPLETED · NA
-
Effects of MDMA on Social and Emotional Processing
COMPLETED · NA
-
Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3
COMPLETED · NA
-
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.